Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib plus topical corticosteroids for moderate to severe atopic dermatitis (Japan, Phase 3)
jRCT2080224137Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in atopic dermatitis (AD) (3 arms), sponsored by Eli Lilly and Company. Started Nov 2018; status: completed.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080224137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224137.